| Therapy | Biomarker/Test | Methodology | Indication |
| Pharmaceutical and surgical prevention options and surveillance | BRCA1, 2 | DNA sequence analysis (gene mutations) |
Hereditary breast and ovarian cancer: Guide surveillance/prevention treatment and on susceptibility risk for breast and ovarian cancer |
| Pharmaceutical and surgical treatment options and surveillance | p16/CDKN2A | DNA sequence analysis (gene mutation) | Melanoma: Guides surveillance/preventive treatment based on susceptibility risk for melanoma |
| Cancer treatment regimens | Oncotype DX 21-gene assay | Reverse Transcription Polymerase Chain Reaction (RNA) | Breast cancer: 21 genes linked to breast cancer recurrence and the benefits from chemotherapy and hormonal therapy |
| Anti-retroviral drugs | TruGene-HIV 1 genotyping kit | DNA sequence analysis (genomic mutations) | HIV: Guides selection of therapy based on genetic variations that make the HIV virus resistant to some anti-retroviral drugs |
| Immunosuppressive drugs | AlloMap gene profile (20 genes) | Quantitative real-time RT-PCR | Heart transplantation: Monitors patient's immune response to heart transplant to guide immunosuppressive therapy |
| Pharmaceutical and lifestyle prevention options | Familion 5-gene profile | Genetic testing for gene mutations | Cardiac rhythm abnormalities |
| Tamoxifen | Estrogen receptor | Immunohistochemistry, ligand binding assay | Breast cancer: help to predict whether adjuvant tamoxifen citrate therapy is likely to beneficial |
| Predictive drug toxicity | Drug absorption, distribution, metabolism, and excretion/elimination (ADME) Panel | Single nucleotide polymorphisms (SNPs) analysis | Drug discovery, pharmokenetics |
| Immune or autoimmune response | Major Histocompatibility Complex (MHC) Panel | Genotyping microassay (SNPs) | Immune system, autoimmunity, and reproductivity |